Institut Pasteur

Hela Saidi

Marie-Lise Gougeon

Valerie Seffer

Beatrice Poirier-Beaudoin

Marie-Therese Melki

Nicole Prada

Maria-Thérèse Melki

Béatrice Poirier-Beaudoin

Valérie Seffer

The quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample, in particular human serum and/or Cerebrospinal Fluid (CSF) is detailed. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved and an in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved are detailed. A kit to quantitate the specific antibodies for at least one redox form of HMGB1, in particular human HMGB1 is detailed.

Assay to detect and quantitate specific antibodies for various redox forms of HMGB1

Quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved. An in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. A kit to quantitate said specific antibodies for at least one redox form of HMGB1.

Assay to detect and quantitate specific an antibodies for various redox forms of HMGB1

Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.

Method for quantitating total HMGB1 protein in biological samples

The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

Growing community of inventors

Paris, France

Hela Saidi